ClinicalTrials.gg
WithdrawnNCT05029609Updated Mar 3, 2022

Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS

A Phase 1 interventional study of Intranasal Foralumab Solution and Placebo in Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis and Multiple Sclerosis, sponsored by Tiziana Life Sciences LTD. Withdrawn. Open to participants aged 25 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-03-03.

Sponsored by Tiziana Life Sciences LTD · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Withdrawn due to business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
25 Years to 70 Years
Sex
All
01

Study summary

The primary objective is to establish the safety of administration of intranasal Foralumab in non-active primary and secondary progressive Multiple Sclerosis (MS) patients in a multiple ascending dose format in escalating doses for 14 consecutive days.

Read the detailed description

This is a Phase 1b double blind, randomized, placebo controlled, dose escalating study evaluating multiple doses of Foralumab via intranasal administration for 14 days in patients with MS.

Up to 55 untreated primary and secondary progressive MS patients will be enrolled, to obtain a total of 48 completed subjects (9 active, 3 placebos per group), allowing for dropouts.

02

Conditions studied

  • Primary Progressive Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis
  • Multiple Sclerosis
03

In context

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Lead sponsor

Tiziana Life Sciences LTD is the lead sponsor of 14 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of MS (according to the 2010 McDonald criteria).
  2. Age 25-70 years.
  3. Clinical diagnosis of non-active primary and secondary MS
  4. MRI imaging consistent with a diagnosis of MS at any time point.
  5. Score on the Expanded Disability Status Scale (EDSS) of 2.5-6.5
  6. Adequate hematologic parameters without ongoing transfusion support:

    • (Hb) ≥ 9 g/dL
    • ≥ 100 x 109 cells/L
  7. Creatinine ≤ 1.5 x the (ULN), or calculated

    ≥ 60 mL/minute x 1.73 m2 per the Cockcroft-Gault formula

  8. Total ≤ 2 times the upper limit of normal (ULN) unless due to Gilbert's disease
  9. (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN, or \< 5 times ULN for patients with liver
  10. corrected for rate (QTcF) ≤ 470 msec for women and ≤ 450 msec for men on the obtained at Screening
  11. Negative serum pregnancy test within 14 days prior to the first dose of study therapy for women of (WCBP)
  1. Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  1. use (oral or intravenous) within the last 30 days.
  2. Current use or use in the prior 6 months of MS immunotherapy, interferon, glatiramer acetate, fingolimod, siponimod, dimethyl fumarate or natalizumab or any other chronic medication
  3. Inability to tolerate intranasally administered medications
  4. Nasal corticosteroids, nasal antihistamines, nasal flu dosing within the past 30 days.
  5. Chronic rhinitis, deviated septum, nasal polyps, history of sinusitis treated within the past 12 months.
  6. Active COVID-19 disease; according to FDA guidelines
  7. Female patient who is pregnant, lactating, breastfeeding, or planning on becoming pregnant during study.
  8. Female patients of childbearing age will undergo a pregnancy test and be excluded from the study if positive.
  9. Active within 5 years.
  10. Inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, asthma, or type 1 diabetes
  11. Neutropenia (\<500 neutrophils/mL) or other severe immunosuppression
  12. Unable or unwilling to comply with protocol requirements.
  13. Patients with a history of gadolinium allergy.
  14. Screening labs outside of the normal range; EBV IgM positive subjects with clinical signs will not receive study drug.
  15. Serious cardiac condition within the last 6 months, such as uncontrolled arrhythmia, myocardial infarction, unstable angina or heart disease defined by the (NYHA) Class III or Class IV (See Appendix B) or hereditary long syndrome
  16. Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes, except for antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered by the Investigator to be essential for patient care
  17. Known positive for (HIV), virus surface antigen (HBsAg) or virus (HCV)
  18. Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Other
    Group A

    Group A will receive nasal Foralumab Dose 1 daily for 14 days (n=9) or placebo (n=3)

    Drug: Intranasal Foralumab Solution · Drug: Placebo

  • Other
    Group B

    Group B will receive nasal Foralumab Dose 2 tiw for 14 days (n=9) or placebo (n=3)

    Drug: Intranasal Foralumab Solution · Drug: Placebo

  • Other
    Group C

    Group C will receive nasal Foralumab Dose 3 daily for 14 days (n=9) or placebo (n=3)

    Drug: Intranasal Foralumab Solution · Drug: Placebo

  • Other
    Group D

    Group D will receive nasal Foralumab Dose 4 daily for 14 days (n=9) or placebo (n=3)

    Drug: Intranasal Foralumab Solution · Drug: Placebo

Interventions

  • The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.

  • DrugPlacebo

    The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.

06

What researchers measure

Primary outcomes

  1. To establish the safety of intranasal foralumab in non-active primary and secondary progressive MS in escalating doses for 14 consecutive days

    Analyses through review of adverse events categorized and graded via CTCAE.

    Time frame: 14 days

Secondary outcomes

  1. Change in Expanded Disability Status Scale (EDSS) at Day 45

    The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. EDSS steps 1.0 to 4.5 refer to people with MS who are able to walk without any aid and is based on measures of impairment in eight functional systems. Lower score indicates that the subject is doing better.

    Time frame: 45 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2021; primary completion for Nov 2022, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2021
First posted
Aug 31, 2021
StartEst.
Oct 2021
Primary completionEst.
Nov 2022
CompletionEst.
Dec 2022
Last update
Mar 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05029609
Lead sponsor
Tiziana Life Sciences LTD
Responsible party
Sponsor
First posted
Aug 31, 2021
Start date
Oct 2021 (estimated)
Primary completion
Nov 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Mar 3, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Foralumab

Start the discussion